The majority of patients with HBeAg-negative chronic hepatitis B treated with peginterferon alpha-2a (40KD) [PEGASYS®] sustain responses 2 years post-treatment

被引：9

作者：

Marcellin, P.

Bonino, F.

Lau, G. K. K.

Farci, P.

Yurdaydin, C.

Piratvisuth, T.

Jin, R.

Gurel, S.

Hadziyannis, S.

Lu, Z. -M.

Popescu, M.

机构：

[1] Hop Beaujon, Serv Hepatol, Clichy, France

[2] Osped Maggiore Milano Policlin, Milan, Italy

[3] Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China

[4] Univ Cagliari, Dipartimento Sci Med, Monserrato, Italy

[5] Ankara Univ, Dept Gastroenterol, Ankara, Turkey

[6] Songklanagarind Hosp, Dept Internal Med, Hat Yai, Thailand

[7] Beijing You An Hosp, Digest Dept, Beijing, Peoples R China

[8] Uludag Univ, Dept Gastroenterol, Uludag, Turkey

[9] Henry Dunant Hosp, Dept Med & Hepatol, Athens, Greece

[10] Ruijin Hosp, Dept Infect Dis, Shanghai, Peoples R China

[11] Roche, Basel, Switzerland

来源：

关键词：

D O I：

10.1016/S0168-8278(06)80744-0

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

743

引用

页码：S275 / S275

页数：1